BioNTech Returns to Profit in Third Quarter, Raises Revenue Guidance

German biotechnology company BioNTech announced that it returned to profitability in the third quarter of 2026, posting a net profit of EUR 184.5 million. This result marks a recovery in the company's financial performance following losses in previous periods. The company also revised its full-year revenue guidance upward. Exceeding previously announced estimates, BioNTech expects total revenue for 2026 to be in the range of EUR 1.7 billion to EUR 1.9 billion. The return to positive net profit and the raised revenue guidance are seen as an improvement in the company's financial statements. BioNTech's third-quarter results indicate that, despite fluctuations in the biotechnology sector, the company is taking steps toward achieving its profitability targets. Not investment advice.